AI Enhanced Portfolio Management in Pharma and Biotech

Introduction

This workflow outlines the integration of AI technologies into portfolio management and resource allocation processes within pharmaceutical and biotechnology companies. It details each step, from project intake to performance monitoring, highlighting how AI can enhance decision-making and optimize resources for more efficient drug development.

AI-Enabled Portfolio Management and Resource Allocation Workflow

1. Project Intake and Initial Assessment

The process commences with the proposal of new drug development projects, which are subsequently entered into the portfolio management system. An AI-powered intake tool, such as Planview’s AI Assistant, can be utilized to:

• Automatically extract key project details from proposal documents.
• Classify and tag projects based on therapeutic area, modality, stage, etc.
• Conduct an initial assessment of strategic fit and potential value.

2. Portfolio Prioritization and Selection

Following this, the portfolio of proposed and ongoing projects is evaluated and prioritized. AI tools, such as Intelligencia’s ASCENT platform, can enhance this step by:

• Analyzing historical data to predict the probability of success for each project.
• Estimating potential market value and return on investment.
• Recommending an optimal portfolio mix based on strategic goals and risk tolerance.

3. Resource Capacity Planning

Once the portfolio is defined, AI is employed to optimize resource allocation across projects. Taltrics’ AI-powered resource management solution can:

• Forecast resource needs based on project plans and historical data.
• Identify potential resource conflicts and bottlenecks.
• Suggest optimal resource assignments based on skills and availability.

4. Project Scheduling and Timeline Optimization

Subsequently, detailed project schedules are created and optimized. An AI scheduling tool, such as OnePlan, can:

• Automatically generate baseline schedules from templates.
• Optimize timelines by analyzing dependencies and constraints.
• Predict likely completion dates using Monte Carlo simulations.

5. Risk Assessment and Mitigation Planning

AI is leveraged to proactively identify and manage risks. Accenture’s AI-based risk management platform can:

• Analyze project data to surface potential risks and issues.
• Quantify risk impacts and probabilities.
• Recommend mitigation strategies based on past project outcomes.

6. Performance Monitoring and Reporting

As projects are executed, AI-powered dashboards and analytics tools monitor performance. Planview’s AI-driven reporting can:

• Automatically detect variances from plans and forecasts.
• Generate natural language summaries of project status.
• Predict future performance based on current trends.

7. Portfolio Rebalancing and Optimization

The portfolio is continuously rebalanced as conditions change. Intelligencia’s ASCENT platform can:

• Dynamically update project success probabilities as new data emerges.
• Recommend portfolio adjustments based on shifting market conditions.
• Simulate “what-if” scenarios to evaluate potential changes.

AI Integration Improvements

This workflow can be further enhanced through deeper AI integration:

• Implement a centralized AI orchestration layer to coordinate data flows and insights across tools.
• Utilize natural language processing to extract insights from unstructured data, such as lab notes and regulatory documents.
• Apply reinforcement learning to continuously improve decision algorithms based on observed outcomes.
• Leverage knowledge graphs to map complex relationships between projects, resources, and strategic objectives.
• Employ computer vision to analyze and interpret scientific imaging data for more accurate progress tracking.

By integrating these advanced AI capabilities, pharmaceutical and biotechnology companies can establish a more adaptive, data-driven approach to portfolio management and resource allocation. This enables faster decision-making, improved resource utilization, and ultimately accelerates the development of life-saving therapies.